Article (Scientific journals)
Exploring the ATN classification system using brain morphology.
Heinzinger, Nils; Maass, Anne; Berron, David et al.
2023In Alzheimer's Research and Therapy, 15 (1), p. 50
Peer Reviewed verified by ORBi
 

Files


Full Text
Exploring the ATN classification system using brain morphology.pdf
Author postprint (2.35 MB)
Download

All documents in ORBilu are protected by a user license.

Send to



Details



Keywords :
ATN; Alzheimer’s disease; Amyloid; Biomarker; MRI; Memory; VBM; Voxel-based morphometry; Amyloid beta-Peptides; Amyloidogenic Proteins; tau Proteins; Biomarkers; Humans; Cross-Sectional Studies; Bayes Theorem; Brain/diagnostic imaging; Alzheimer Disease/diagnostic imaging; Cognitive Dysfunction/diagnostic imaging; Brain; Cognitive Dysfunction; Neurology; Neurology (clinical); Cognitive Neuroscience
Abstract :
[en] [en] BACKGROUND: The NIA-AA proposed amyloid-tau-neurodegeneration (ATN) as a classification system for AD biomarkers. The amyloid cascade hypothesis (ACH) implies a sequence across ATN groups that patients might undergo during transition from healthy towards AD: A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+. Here we assess the evidence for monotonic brain volume decline for this particular (amyloid-conversion first, tau-conversion second, N-conversion last) and alternative progressions using voxel-based morphometry (VBM) in a large cross-sectional MRI cohort. METHODS: We used baseline data of the DELCODE cohort of 437 subjects (127 controls, 168 SCD, 87 MCI, 55 AD patients) which underwent lumbar puncture, MRI scanning, and neuropsychological assessment. ATN classification was performed using CSF-Aβ42/Aβ40 (A+/-), CSF phospho-tau (T+/-), and adjusted hippocampal volume or CSF total-tau (N+/-). We compared voxel-wise model evidence for monotonic decline of gray matter volume across various sequences over ATN groups using the Bayesian Information Criterion (including also ROIs of Braak stages). First, face validity of the ACH transition sequence A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was compared against biologically less plausible (permuted) sequences among AD continuum ATN groups. Second, we evaluated evidence for 6 monotonic brain volume progressions from A-T-N- towards A+T+N+ including also non-AD continuum ATN groups. RESULTS: The ACH-based progression A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was consistent with cognitive decline and clinical diagnosis. Using hippocampal volume for operationalization of neurodegeneration (N), ACH was most evident in 9% of gray matter predominantly in the medial temporal lobe. Many cortical regions suggested alternative non-monotonic volume progressions over ACH progression groups, which is compatible with an early amyloid-related tissue expansion or sampling effects, e.g., due to brain reserve. Volume decline in 65% of gray matter was consistent with a progression where A status converts before T or N status (i.e., ACH/ANT) when compared to alternative sequences (TAN/TNA/NAT/NTA). Brain regions earlier affected by tau tangle deposition (Braak stage I-IV, MTL, limbic system) present stronger evidence for volume decline than late Braak stage ROIs (V/VI, cortical regions). Similar findings were observed when using CSF total-tau for N instead. CONCLUSION: Using the ATN classification system, early amyloid status conversion (before tau and neurodegeneration) is associated with brain volume loss observed during AD progression. The ATN system and the ACH are compatible with monotonic progression of MTL atrophy. TRIAL REGISTRATION: DRKS00007966, 04/05/2015, retrospectively registered.
Disciplines :
Neurology
Author, co-author :
Heinzinger, Nils;  German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany. nils.heinzinger@st.ovgu.de ; Institute of Cognitive Neurology and Dementia Research (IKND), University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany. nils.heinzinger@st.ovgu.de
Maass, Anne;  German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute of Cognitive Neurology and Dementia Research (IKND), University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany
Berron, David;  German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute of Cognitive Neurology and Dementia Research (IKND), University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany
Yakupov, Renat;  German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute of Cognitive Neurology and Dementia Research (IKND), University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany
Peters, Oliver;  German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Fiebach, Jochen;  Center for Stroke Research Berlin, Charité-Universitätsmedizin, Berlin, Germany
Villringer, Kersten;  Center for Stroke Research Berlin, Charité-Universitätsmedizin, Berlin, Germany
Preis, Lukas;  Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Priller, Josef;  German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany ; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany ; University of Edinburgh and UK DRI, Edinburgh, UK
Spruth, Eike Jacob;  German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany
Altenstein, Slawek;  German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany
Schneider, Anja;  German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Geriatric Psychiatry/Psychiatry, University of Bonn Medical Center, Bonn, Germany
Fliessbach, Klaus;  German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Geriatric Psychiatry/Psychiatry, University of Bonn Medical Center, Bonn, Germany
Wiltfang, Jens;  German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany ; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany ; Department of Medical Sciences, Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal
Bartels, Claudia;  Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany
Jessen, Frank;  German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany ; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
Maier, Franziska;  Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany
Glanz, Wenzel;  German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
Buerger, Katharina;  German Center for Neurodegenerative Diseases (DZNE), Munich, Germany ; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
Janowitz, Daniel;  Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
Perneczky, Robert;  German Center for Neurodegenerative Diseases (DZNE), Munich, Germany ; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany ; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany ; Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK
Rauchmann, Boris-Stephan;  Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
Teipel, Stefan;  German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany
Killimann, Ingo;  German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany
Göerß, Doreen;  Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany
Laske, Christoph;  German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany ; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
Munk, Matthias H;  German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany ; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
Spottke, Annika;  German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurology, University of Bonn, Bonn, Germany
Roy, Nina;  German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
HENEKA, Michael  ;  German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Geriatric Psychiatry/Psychiatry, University of Bonn Medical Center, Bonn, Germany
Brosseron, Frederic;  German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Geriatric Psychiatry/Psychiatry, University of Bonn Medical Center, Bonn, Germany
Dobisch, Laura;  German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
Ewers, Michael;  German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Dechent, Peter;  MR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-University Göttingen, Göttingen, Germany
Haynes, John Dylan;  Bernstein Center for Computational Neuroscience, Charité-Universitätsmedizin, Berlin, Germany
Scheffler, Klaus;  Department for Biomedical Magnetic Resonance, University of Tübingen, Tübingen, Germany
Wolfsgruber, Steffen;  German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Geriatric Psychiatry/Psychiatry, University of Bonn Medical Center, Bonn, Germany
Kleineidam, Luca;  German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Schmid, Matthias;  German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Institute for Medical Biometry, University Hospital Bonn, Bonn, Germany
Berger, Moritz;  Institute for Medical Biometry, University Hospital Bonn, Bonn, Germany
Düzel, Emrah;  German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute of Cognitive Neurology and Dementia Research (IKND), University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany
Ziegler, Gabriel;  German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute of Cognitive Neurology and Dementia Research (IKND), University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Str. 44, 39120, Magdeburg, Germany
Alzheimer’s Disease Neuroimaging Initiative
More authors (33 more) Less
External co-authors :
yes
Language :
English
Title :
Exploring the ATN classification system using brain morphology.
Publication date :
13 March 2023
Journal title :
Alzheimer's Research and Therapy
eISSN :
1758-9193
Publisher :
BioMed Central Ltd, England
Volume :
15
Issue :
1
Pages :
50
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
Otto-von-Guericke-Universität Magdeburg
Funding text :
Open Access funding enabled and organized by Projekt DEAL. The study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)), reference number BN012.Data collection and sharing for the ADNI dataset in this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. ADNI is further funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and by contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health.
Available on ORBilu :
since 22 July 2024

Statistics


Number of views
46 (0 by Unilu)
Number of downloads
20 (0 by Unilu)

Scopus citations®
 
9
Scopus citations®
without self-citations
7
OpenCitations
 
3
OpenAlex citations
 
11
WoS citations
 
8

Bibliography


Similar publications



Contact ORBilu